Phaseline

Targets › KDR

KDR (Vascular endothelial growth factor receptor 2): drug programs, companies and trials

32 programs from 29 companies in 513 trials: 372 Phase 2, 65 Phase 1, 64 Phase 3, 12 Phase 4; Oncology, Other, Respiratory; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. (UniProt, P35968)

Open in Phaseline: the race on KDR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupCatequentinib
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 4Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma …Dec 2026
ExelixisCabozantinib (XL184)
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 4Medullary Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Prostate Cancer; Renal Cell Carcinoma …Jan 2027
TakedaFruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 4Colorectal CancerOct 2027
Eli LillyRamucirumab (LY3009806)
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 3Metastatic Non-Small Cell Lung Cancer; Biliary Tract Cancer; Neoplasms; Recurrent Lung Non-Small Cell Carcinoma …Dec 2026
National Cancer Institute (NCI)Cabozantinib S-malate
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 3Functioning Pancreatic Neuroendocrine Tumor; Clear Cell Renal Cell Carcinoma; Advanced Bladder Urothelial Carcinoma; Differentiated Thyroid Gland Carcinoma …Dec 2026
Shanghai Junshi Bioscience Co., Ltd.Lenvatinib mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Hepatocellular Carcinoma (HCC); Intrahepatic CholangiocarcinomaDec 2026
Ocular TherapeutixAxitinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) …Jan 2027
University Hospital, BordeauxPD-1/PD-L1 ICI + VEGFR-TKI combination
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDR, FLT1, FLT4Phase 3Metastatic Renal Cell CarcinomaJan 2027
Merck & Co. (MSD)Lenvatinib (MK-7902)
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma …Feb 2027
Advenchen LaboratoriesCatequentinib (AL3818)
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 3Alveolar Soft Part SarcomaDec 2027
AO GENERIUMGNR-139
Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2
FLT1, KDR, FLT4Phase 3nAMDMay 2028
Hutchmedfruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Endometrial Cancer; Advanced Renal Cell CarcinomaJan 2029
Alliance for Clinical Trials in OncologyTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 3Clear Cell Renal Cell CarcinomaNov 2037
Jiangsu HengRui MedicineRivoceranib Mesylate
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 3Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); BCLC Stage C Hepatocellular Carcinoma …–
Avalyn PharmaNintedanib (AP02)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer …Dec 2026
Henan Cancer HospitalLenvatinib Mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2EffectivenessDec 2026
Chipscreen BiosciencesIbcasertib
Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor
AURKB, FLT1, FLT4, KDRPhase 2Pancreatic Ductal AdenocarcinomaFeb 2027
M.D. Anderson Cancer CenterCabozantinib S-malate
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 2Malignant Neoplasms of Urinary Tract; Locally Advanced Osteosarcoma; Brain Metastases; Advanced Breast Carcinoma …Apr 2027
City of Hope Medical CenterLenvatinib Mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Advanced Pancreatic Ductal Adenocarcinoma; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Apr 2027
Tianjin Medical University Cancer Institute and HospitalAnlotinib Hydrochloride
multi-target tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR inhibitor)
KDR, PDGFRA, FLT4Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerJun 2027
Jinling Hospital, ChinaPD-1/PD-L1 ICI + VEGFR-TKI
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDRPhase 2Renal Cell Carcinoma (RCC)Aug 2027
MannkindNintedanib (MNKD-201)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary FibrosisDec 2027
GrandPharma (China)Rivoceranib
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 2HCCDec 2027
CriteriumFruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma …Dec 2027
HutchmedSurufatinib
Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor
FGFR1, FLT1, FLT4, KDRPhase 2Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma …May 2028
M.D. Anderson Cancer CenterTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 2Renal Cell CarcinomaNov 2028
Guangzhou Virotech PharmaceuticalRivoceranib
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 2HCC; Hepatocellular Carcinoma; Advanced Breast Cancer; Acral Melanoma …Dec 2028
University of FloridaTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1Bile Duct CancerDec 2026
Betta PharmaceuticalsX-82
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 1DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib …Jan 2027
Ottimo PharmaOTP-01
Dual paratopic PD-1/VEGFR2 antibody
PDCD1, KDRPhase 1Advanced Solid TumorsDec 2028
National Cancer Institute (NCI)Tivozanib (AV-951)
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1CholangiocarcinomaDec 2028
Sun Yat-sen UniversityKDR2-2 suspension eyedrop
VEGFR2 inhibitor with moderate PDGFRβ inhibition
KDR, PDGFRBPhase 1Neovascular Glaucoma–

Conditions

Hepatocellular Carcinoma (23) Gastric Cancer (12) Colorectal Cancer (12) Metastatic Renal Cell Carcinoma (10) HCC (8) Hepatocellular Carcinoma Non-resectable (8) Breast Cancer (8) Renal Cell Carcinoma (7) Intrahepatic Cholangiocarcinoma (7) Clear Cell Renal Cell Carcinoma (7) Hepatocellular Carcinoma (HCC) (7) Non Small Cell Lung Cancer (7)

Modalities

small molecule (16), mixed (15), antibody (1)

Companies

National Cancer Institute (NCI) (2) M.D. Anderson Cancer Center (2) Hutchmed (2) Exelixis (1) Merck & Co. (MSD) (1) University Hospital, Bordeaux (1) Jiangsu HengRui Medicine (1) Chia Tai Tianqing Pharmaceutical Group (1) Takeda (1) Tianjin Medical University Cancer Institute and Hospital (1) AO GENERIUM (1) Chipscreen Biosciences (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Shanghai Junshi Bioscience Co., Ltd. (1) University of Florida (1) Mannkind (1) Sun Yat-sen University (1) Advenchen Laboratories (1) Guangzhou Virotech Pharmaceutical (1)

Related targets

FLT4 (22) FLT1 (19) PDGFRB (10) KIT (6) PDGFRA (4) MET (3) PDCD1 (3) CD274 (2) AURKB (1) FGFR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.